209 related articles for article (PubMed ID: 34588735)
1. A CHILD WITH DENSE DEPOSIT DISEASE AND DECREASED CLASSIC COMPLEMENT PATHWAY ACTIVITY.
Trutin I; Oletić L; Galešić Ljubanović D; Turudić D; Milošević D
Acta Clin Croat; 2021 Mar; 60(1):141-145. PubMed ID: 34588735
[TBL] [Abstract][Full Text] [Related]
2. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies.
Servais A; Noël LH; Roumenina LT; Le Quintrec M; Ngo S; Dragon-Durey MA; Macher MA; Zuber J; Karras A; Provot F; Moulin B; Grünfeld JP; Niaudet P; Lesavre P; Frémeaux-Bacchi V
Kidney Int; 2012 Aug; 82(4):454-64. PubMed ID: 22456601
[TBL] [Abstract][Full Text] [Related]
3. Streptococcal infection as possible trigger for dense deposit disease (C3 glomerulopathy).
Prasto J; Kaplan BS; Russo P; Chan E; Smith RJ; Meyers KE
Eur J Pediatr; 2014 Jun; 173(6):767-72. PubMed ID: 24384791
[TBL] [Abstract][Full Text] [Related]
4. Rituximab fails where eculizumab restores renal function in C3nef-related DDD.
Rousset-Rouvière C; Cailliez M; Garaix F; Bruno D; Laurent D; Tsimaratos M
Pediatr Nephrol; 2014 Jun; 29(6):1107-11. PubMed ID: 24408225
[TBL] [Abstract][Full Text] [Related]
5. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement.
Sethi S; Fervenza FC; Zhang Y; Nasr SH; Leung N; Vrana J; Cramer C; Nester CM; Smith RJ
Clin J Am Soc Nephrol; 2011 May; 6(5):1009-17. PubMed ID: 21415311
[TBL] [Abstract][Full Text] [Related]
6. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.
Ozkaya O; Nalcacioglu H; Tekcan D; Genc G; Meydan BC; Ozdemir BH; Baysal MK; Keceligil HT
Pediatr Nephrol; 2014 Jul; 29(7):1283-7. PubMed ID: 24464478
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort.
Michels MAHM; Wijnsma KL; Kurvers RAJ; Westra D; Schreuder MF; van Wijk JAE; Bouts AHM; Gracchi V; Engels FAPT; Keijzer-Veen MG; Dorresteijn EM; Volokhina EB; van den Heuvel LPWJ; van de Kar NCAJ
Pediatr Nephrol; 2022 Mar; 37(3):601-612. PubMed ID: 34476601
[TBL] [Abstract][Full Text] [Related]
8. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy.
Noris M; Donadelli R; Remuzzi G
Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306
[TBL] [Abstract][Full Text] [Related]
9. Dense deposit disease in a child with febrile sore throat.
Conti G; De Vivo D; Vitale A; Fede C; Santoro D
Saudi J Kidney Dis Transpl; 2017; 28(4):925-928. PubMed ID: 28748900
[TBL] [Abstract][Full Text] [Related]
10. Causes of alternative pathway dysregulation in dense deposit disease.
Zhang Y; Meyer NC; Wang K; Nishimura C; Frees K; Jones M; Katz LM; Sethi S; Smith RJ
Clin J Am Soc Nephrol; 2012 Feb; 7(2):265-74. PubMed ID: 22223606
[TBL] [Abstract][Full Text] [Related]
11. C3 nephritic factor associated with C3 glomerulopathy in children.
Nicolas C; Vuiblet V; Baudouin V; Macher MA; Vrillon I; Biebuyck-Gouge N; Dehennault M; Gié S; Morin D; Nivet H; Nobili F; Ulinski T; Ranchin B; Marinozzi MC; Ngo S; Frémeaux-Bacchi V; Pietrement C
Pediatr Nephrol; 2014 Jan; 29(1):85-94. PubMed ID: 24068526
[TBL] [Abstract][Full Text] [Related]
12. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
13. C3 glomerulopathy.
Servais A; Noël LH; Frémeaux-Bacchi V; Lesavre P
Contrib Nephrol; 2013; 181():185-93. PubMed ID: 23689580
[TBL] [Abstract][Full Text] [Related]
14. Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.
Kumar A; Nada R; Ramachandran R; Rawat A; Tiewsoh K; Das R; Rayat CS; Gupta KL; Vasishta RK
J Nephrol; 2020 Jun; 33(3):539-550. PubMed ID: 31820418
[TBL] [Abstract][Full Text] [Related]
15. C3 Glomerulopathy.
Riedl M; Thorner P; Licht C
Pediatr Nephrol; 2017 Jan; 32(1):43-57. PubMed ID: 27056062
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of C3 glomerulopathy in children: a single-center experience.
Drake KA; Ellington N; Gattineni J; Torrealba JR; Hendricks AR
Pediatr Nephrol; 2020 Jan; 35(1):153-162. PubMed ID: 31667615
[TBL] [Abstract][Full Text] [Related]
17. Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.
Viswanathan GK; Nada R; Kumar A; Ramachandran R; Rayat CS; Jha V; Sakhuja V; Joshi K
Diagn Pathol; 2015 Mar; 10():6. PubMed ID: 25889427
[TBL] [Abstract][Full Text] [Related]
18. C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.
Zhang Y; Meyer NC; Fervenza FC; Lau W; Keenan A; Cara-Fuentes G; Shao D; Akber A; Fremeaux-Bacchi V; Sethi S; Nester CM; Smith RJH
Am J Kidney Dis; 2017 Dec; 70(6):834-843. PubMed ID: 28838767
[TBL] [Abstract][Full Text] [Related]
19. Dense deposit disease and C3 glomerulopathy.
Barbour TD; Pickering MC; Terence Cook H
Semin Nephrol; 2013 Nov; 33(6):493-507. PubMed ID: 24161036
[TBL] [Abstract][Full Text] [Related]
20. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy.
Bomback AS; Santoriello D; Avasare RS; Regunathan-Shenk R; Canetta PA; Ahn W; Radhakrishnan J; Marasa M; Rosenstiel PE; Herlitz LC; Markowitz GS; D'Agati VD; Appel GB
Kidney Int; 2018 Apr; 93(4):977-985. PubMed ID: 29310824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
